Lv3
400 积分 2025-04-11 加入
A renaissance in targeting the PI3K/AKT/mTOR pathway
22小时前
待确认
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025)
9天前
已完结
Translational Medicine in Hormone Receptor–Positive Breast Cancer: The Journey of Inavolisib (Itovebi™) from Mutation to Clinical Success
10天前
已完结
Selective CDK2 Degradation via Noncanonical Recruitment
12天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
15天前
已完结
STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
1个月前
已完结
Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer
1个月前
已完结
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
2个月前
已完结
When, where and which PIK3CA mutations are pathogenic in congenital disorders
2个月前
已完结
Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants
2个月前
已完结
皖公网安备34019202002308
